9月11日 - ** 制药商艾伯维ABBV.N股价盘前上涨5.4%至223美元
** 该公司表示，它已与所有向美国食品和药物管理局提交了类风湿关节炎药物upadacitinib（品牌为Rinvoq）仿制药上市申请的制造商就 (link) 诉讼达成了和解。
** 根据协议，预计 2037 年 4 月之前不会有任何奥达帕替尼片剂的仿制药进入美国市场。
** 截至上次收盘，股价年累计上涨 19
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.